The Valley Desk

NCT07711002 · Interventional trial

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Overall registry status Recruiting

Phase 3

Conditions Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov